Single-cell sequencing of peripheral blood cells in SLE patients

系统性红斑狼疮(SLE)长期以来一直以1型的典型表达为特征 干扰素诱导基因(IFIG)。然而，由于许多IFIG的多向性作用，有多大的不同 外周血单核细胞(PBMCs)介导型干扰素信号导致疾病在很大程度上 未知。在这里，我们建议使用基于液滴的rna测序来研究PBMC的干扰素反应。 来自狼疮患者和健康对照。利用自然产生的“遗传条形码”，我们将开发一种 极具创新性的多路传输策略，可显著提高吞吐量、降低成本并限制 目前基于液滴的RNA测序技术存在不必要的技术噪音。我们将发展 将单个细胞分配给来源供体并去除不需要的液滴的计算算法 包含多个单元格。我们将使用多路传输策略来生成丰富的数据集(总单元数约为25万 首次实现了对β-干扰素对外周血单核细胞的影响的无偏见表征 分类。我们将首先比较8名健康对照、8名狼疮性肾炎和8名狼疮性肾炎患者的PBMC，以确定 预测疾病状态和严重程度的细胞类型特异性干扰素-β反应特征。这些 签名可以用来更好地监测狼疮的进展和治疗反应。通过分析PBMC 从分型的狼疮患者中，我们将描述常见的基因变异是如何影响的 对干扰素-β的特定细胞类型的应答，包括表达参数(例如，单个 细胞)不可能从批量RNA测序中获得。这些结果可以与遗传变异进行比较。 通过全基因组关联研究确定与狼疮相关，以更好地了解分子 疾病的病理学。

Systemic lupus erythematosus (SLE) has long been characterized by the prototypical expression of type-1 interferon induced genes (IFIGs). However, because of the pleiotropic roles of many IFIGs, how different peripheral blood mononuclear cells (PBMCs) mediate type-1 interferon signaling to cause disease is largely unknown. Here, we propose to use droplet-based RNA-sequencing to study the interferon response of PBMCs from lupus patients and healthy controls. Leveraging naturally occurring “genetic barcodes”, we will develop a highly innovative multiplexing strategy that significantly increases the throughput, reduces the cost, and limits unwanted technical noise of current droplet-based RNA-sequencing technologies. We will develop computational algorithms for assigning individual cells to the donor of origin and removing unwanted droplets containing multiple cells. We will use the multiplexing strategy to generate a rich dataset (~250K total cells) that enables, for the first time, the unbiased characterization of the effects of interferon-beta on PBMCs without sorting. We will first compare PBMCs from 8 healthy controls, 8 lupus and 8 lupus nephritis patients, to identify cell-type-specific interferon-beta response signatures that is predictive of disease status and severity. These signatures could be used to better monitor lupus progression and treatment response. By profiling PBMCs from 64 genotyped lupus patients, we will then characterize how common genetic variants affect cell-type-specific responses to interferon-beta, including expression parameters (e.g. variance across single cells) impossible to obtain from bulk RNA-sequencing. These results could be compared to genetic variants associated with lupus identified by genome-wide association studies to better understand the molecular pathology of the disease.